EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSAPEG00000018898
Gene Symbol: F2RL3
1 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSAPEG00000023441
Gene Symbol: FAUA
1 Cross references
299 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSAPEG00000015022
Gene Symbol: FYNA
1 Cross references
192 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSAPEG00000003775
Gene Symbol: FYNB
1 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSAPEG00000001588
Gene Symbol: GPR119
2 Cross references
176 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSAPEG00000016838
Gene Symbol: HCK
1 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSAPEG00000010858
Gene Symbol: ITK
1 Cross references
208 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1a

Ensembl ID : ENSAPEG00000012919
Gene Symbol: IMPDH1A
2 Cross references
259 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSAPEG00000007301
Gene Symbol: IMPDH1B
2 Cross references
258 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSAPEG00000015339
Gene Symbol: IMPDH2
2 Cross references
202 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSAPEG00000010718
Gene Symbol: JAK1
1 Cross references
214 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSAPEG00000007819
Gene Symbol: JAK2A
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).